Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430886 | 0.83 | ABL1 (0.37) | NR1H4ABL1SRC | |
| SCHEMBL1735588 | 0.77 | POLB (0.39) | LMNAMCL1AKT1MEN1KMT2A | |
| SCHEMBL2475267 | 0.76 | MCL1 (0.38) | TP53NR1H4MCL1MEN1KMT2A | |
| SCHEMBL4273631 | 0.74 | MAPT (0.49) | TP53MAPTLMNAMMP2MEN1 | |
| SCHEMBL1652997 | 0.73 | KDM4E (0.47) | MAPTABL1SRCMMP2 | |
| SCHEMBL4268189 | 0.72 | MAPT (0.49) | TP53MAPTLMNARXFP1MEN1 | |
| SCHEMBL14910299 | 0.71 | KDM4E (0.40) | MAPTLMNAMCL1AKT1MEN1 | |
| SCHEMBL26631541 | 0.70 | DHODH (0.38) | MCL1AKT1 | |
| SCHEMBL30139014 | 0.70 | DHODH (0.38) | MCL1AKT1 | |
| SCHEMBL14291609 | 0.70 | POLB (0.45) | LMNAMCL1AKT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1787991-B2 | PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-24 | — | — | EP | disclosed |
| US-20180148446-A1 | PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-31 | — | — | US | disclosed |
| EP-1787991-B1 | PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1787991-A1 | PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148446-A1 | PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | PGA5, ATP6AP1, PPA1 | TP53 3354/4885MAPT 4099/4885LMNA 3382/4885 |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | PGA5, ATP6AP1, PPA1 | TP53 3354/4885MAPT 4099/4885LMNA 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.